Evidence map›Paper›PMID 36980699›Full record

ReviewCancers2023

The Potential Revolution of Cancer Treatment with CRISPR Technology.

Dimitrios Stefanoudakis, Nikhita Kathuria-Prakash, Alexander W Sun, Melissa Abel, Claire E Drolen, Camille Ashbaugh, Shiliang Zhang, Gavin Hui, Yeganeh A Tabatabaei, Yuliya Zektser and 3 more

Full text readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cancers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Review
  11. Review
  12. Article
  13. Review
  14. Review
  15. Article
  16. Review
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Dimitrios StefanoudakisSchool of Medicine, National & Kapodistrian University of Athens, 15772 Athens, Greece.ORCID 0000-0002-2203-0644
Nikhita Kathuria-PrakashDivision of Hematology and Oncology, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA.ORCID 0000-0002-0370-5650
Alexander W SunDepartment of Internal Medicine, Columbia University, New York, NY 10027, USA.
Melissa AbelDivision of Hematology and Oncology, National Cancer Institute, National Institutes of Health, Bethesda, MD 20814, USA.ORCID 0000-0001-8941-0206
Claire E DrolenDepartment of Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA.
Camille AshbaughDepartment of Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA.
Shiliang ZhangDepartment of Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA.
Gavin HuiDivision of Hematology and Oncology, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA.
Yeganeh A TabatabaeiDivision of Hematology and Oncology, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA.
Yuliya ZektserDepartment of Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA.
Lidia P LopezDivision of Hematology and Oncology, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA.
Allan PantuckDepartment of Urology, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA.
Alexandra DrakakiDivision of Hematology and Oncology, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA.ORCID 0000-0001-8865-3548

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Immuno-oncology (IO) and targeted therapies, such as small molecule inhibitors, have changed the landscape of cancer treatment and prognosis; however, durable responses have been difficult to achieve due to tumor heterogeneity, development of drug resistance, and adverse effects that limit dosing and prolonged drug use. To improve upon the current medicinal armamentarium, there is an urgent need for new ways to understand, reverse, and treat carcinogenesis. Clustered regularly interspaced short palindromic repeats (CRISPR)-CRISPR-associated protein (Cas) 9 is a powerful and efficient tool for genome editing that has shown significant promise for developing new therapeutics. While CRISPR/Cas9 has been successfully used for pre-clinical cancer research, its use in the clinical setting is still in an early stage of development. The purpose of this review is to describe the CRISPR technology and to provide an overview of its current applications and future potential as cancer therapies.

Indexed as

cancer preventioncancer therapiesCRISPRCRISPR/Cas9gene-editingnovel therapiesoncologytechnology

Identifiers

PMID36980699
PMCPMC10046289

What OpenQuestion holds

Textfull text, public
LicenceCC BY
measurements read4
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.